

2024 Annual Meeting

12 November 2024 Bali, Indonesia



Driving innovation from discovery to access

Overview and Key Outcomes: 7th Global Forum on TB Vaccines



7th Global Forum on TB Vaccines 8 – 10 October 2024 Rio de Janeiro, Brazil




- First Global Forum convened in the Americas
- Nearly 340 registrations from 34 countries
- More than 120 participants identified as **early career researchers**
- Convened under the overarching theme "Driving innovation from discovery to access", program addressed the full spectrum of research and development and explored strategies to ensure new TB vaccines reach the populations that most need them and to maximize the public health impact
- Program was developed around five thematic tracks, aligned with global frameworks for TB vaccine development and implementation
- 85 speakers across 20 plenary, oral abstract, discussion, and poster viewing sessions



Opening and Closing Sessions





Keynote address by WHO Chief Scientist Jeremy Farrar



Secretary of Health Surveillance and Environmental Health Ethel Maciel and Brazil Vaccine Mascot Zé Gontinha welcome participants



Opening panel discussion with Suvanand Sahu (Stop TB Partnership), Mario Moreira (Fiocruz), Nina Russell (Gates Foundation), Ruben Rizzi (BioNTech, Mark Hatherill (SATVI) and Ethel Maciel (Ministry of Health)



Lucica Ditiu (Stop TB Partnership) and Michel Kazatchkine give remarks during the Closing Session





Diversifying the TB Vaccine Pipeline

David Lewinsohn





Program-at-a-glance




Time	Tuesday, 8 October	Wednesday, 9 October	Thursday, 10 October	Friday, 11 October		
08:30 - 09:00	Poster Set-up	Arrival Coffee Networking	Arrival Coffee Networking			
09:00 – 09:30	Registration Coffee					
09:30 - 10:00	Poster Viewing	Plenary 3: Advancing TB vaccine clinical development: Learning from experience	Plenary 5: Innovative approaches to TB			
10:00 - 10:30		& looking to the future	vaccine development			
10:30 – 11:00						
11:00 - 11:30	Opening Session & Keynote Address	Coffee/Tea Break	Coffee/Tea Break			
11:30 - 12:00		• Oral Abstract Sessions • OAI: Mechanisms of biomarkers &	O m Abstract Sessions			
12:00 - 12:30		protection, novel approaches, human	• JA3: Improved formulation & delivery platforms, preclinical research			
12:30 - 13:00	Lunch	 chanenge, eptimizing enimel models OA2: Advancing clinical development 	• 244: Impact, implementation, policy			
13:00 - 13:30	Editori			Site Visits		
13:30 - 14:00		Lunch	Lunch			
14:00 - 14:30	Plenary 1: From discovery to access		Discussion Sessions (x3)			
14:30 – 15:00		Plenary 4: Country scale-up & implementation of new TB vaccines	Discussion sessions (x5)			
15:00 - 15:30		implementation of new 1B vaccines	Break (iStriatica)			
15:30 -16:00	Break Poster Viewing		Plenary 6: Enabling TB vaccine development through funding, political will, open science, & engaged			
16:00 – 16:30		Break Poster Viewing	communities			
16:30 – 17:00			Closing Session			
17:00 - 17:30	Plenary 2: Global & regional enablers for the introduction of new TB vaccines					
17:30 – 18:00		Poster Discussion Sessions (x3)	Free Evening			
18:00 - onward	Welcome Reception (Until 20:00)	Free Evening				
This is a preliminary pr	ogram and subject to change		🗙 @GlobForun	nTBVax #7GFTBV #GlobalForum ⁻		

TB Vaccine Pipeline

Vaccine candidates under clinical development

There are 15 vaccine candidates in the pipeline as of September 2024, of which 12 are in active trials. The candidates are placed under the phase which corresponds to the most advanced ongoing or completed trial.




Candidate target population

- 8 Elderly Adults 8 Adolescents Children Infants X People living with HIV -Mtb People without Mtb infection +Mtb People with Mtb infection aTBd People with active TB disease
- MDR People with MDR-TB

cTB People cured of active TB





Information reported by vaccine sponsors or found in clinical trial registries or other public sources

Institutions listed are vaccine sponsors and development partners

Additional information, including the full list of clinical trials for each candidate, can be accessed via the OR code or at newtbyaccines.org/tb-vaccine-pipeline/ Last update: 2 September 2024

Ø

 \bigcirc

 \checkmark

\$1

 \checkmark

 \checkmark

 \checkmark



Key Topics Addressed



Efforts to develop biomarkers, correlates of protection, and measure of bacterial burden

- Lessons learned from the M72 prevention of disease trial (Nemes) and the H56:IC31 prevention of recurrence trial (Scriba, Mendelsohn)
- Intravenous BCG in nonhuman primates (Darrah, Verreck)
- Aerosol BCG (Li)
- Understanding bacterial burden through the lymph node (Young) *Increase diversity through novel approaches and delivery platforms*
- Increasing the diversity of antigens (Ogongo)
- Explore novel delivery platforms for TB vaccines, including selfadjuvanting vaccines (Tran et al) and RNA (Fulton, Kovalchuke)
- Co-infection (Cohen) and humanized mouse model (Trentini) for clearance of infection





Highlights

CONTRIVENTIAL DEVICES

Optimize animal models to better reflect human disease

- Ultra low-dose (Plumlee, Fulton) and NHP models (Verreck, Darrah) for prevention of infection
- Using the mouse co-infection (Plumlee) and humanized mouse as a model for immunotherapy (Trentini) for clearance of infection

Human challenge model/Controlled human infection model

 Progress and lessons learned in developing an aerosol BCG human challenge model





Accelerating Clinical Development

Ann Ginsberg

(no slides)







Ensuring Public Heath Impact & Implementation of New TB Vaccines

Richard White





Highlights



Impressive country preparedness

Preparing the landscape for TB vaccines: South Africa's strategic planning

First data on new (TB) vaccine acceptability

- Generic vaccines in TB HBCs
- TB Vx HCW/community in Zambia; pregnant women in 4 countries; adolescents in Khayelitsha; adolescents in Mozambique
- Standardised survey questions available

Useful modelling/framework activities

- What to do if vaccine doses are limited? & Fair allocation frameworks?
- TB vaccine impact models being developed <u>in</u> LMICs India at conf (Jessy); S Africa, Indonesia, Brazil coming...



CONTRIBUTION BILD OCTOBER 2024 Rio de Janeiro, Brazi Driving innovation from discovery to access

Highlights

Impressive country preparedness

 Preparing the landscape for TB vaccines: South Africa's strategic planning

First data on new (TB) vaccine acceptability

- Generic vaccines in TB HBCs
- TB Vx HCW/community in Zambia; pregnant women in 4 countries; adolescents in Khayelitsha; adolescents in Mozambique
- Standardised survey questions available

Useful modelling/framework activities

- What to do if vaccine doses are limited? & Fair allocation frameworks?
- TB vaccine impact models being developed <u>in</u> LMICs India at conf (Jessy); S Africa, Indonesia, Brazil coming...



Preparing the landscape for TB vaccines: South Africa's strategic planning



Ndjeka et al, S Africa MoH

Describe country preparedness

South Africa has prioritised vaccine preparedness as reflected in the NTP Strategic Plan, 2023-28. In collaboration with the national TB Think Tank and NAGI, preparatory work for the introduction of TB vaccines is currently in progress

Three TB vaccine-related activities were prioritised in South Africa's TB Strategic Plan 2023-28

A new indicator was introduced to monitor provincial TB vaccine readiness

ŶŶŶ

A TB Vaccine Working Group was established in the National Advisory Group on Immunization (NAGI)

South Africa's Health Minister sits on World Health Organization's TB Vaccine Accelerator Council

=> Encouraging

Highlights



Impressive country preparedness

Preparing the landscape for TB vaccines: South Africa's strategic planning

First data on new (TB) vaccine acceptability

- Generic vaccines in TB HBCs
- TB Vx HCW/community in Zambia; pregnant women in 4 countries; adolescents in Khayelitsha; adolescents in Mozambique
- Standardised survey questions available

Useful modelling/framework activities

- What to do if vaccine doses are limited? & Fair allocation frameworks?
- TB vaccine impact models being developed <u>in</u> LMICs India at conf (Jessy); S Africa, Indonesia, Brazil coming...



New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?



Hesketh et al, GAVI/LSHTM

Analysis of existing vax confidence data in TB HBCs

Of the 18 countries included, 14 had an overall 2023 vaccine confidence score of 80% or higher. Four countries had a score over 90%: Vietnam (98.5%), Ethiopia (95.5%), India (91.8%), and Sierra Leone (90.6%).

Cameroon had the lowest score with 63.0% followed by Ukraine (66.2%), Russia (70.5%), and South Africa (75.5%). These four countries make up 5.75% of the total TB burden in our sample and may require future attention to ensure confidence in a new TB vaccine.

Country	Estimated number of incident TB cases in 2022	Combined vaccine confidence score for 2023 (% positive)	Difference in combined vaccine score compared to 2022 (% difference)
India	2,820,000	91.8	-4.8
Indonesia	1,060,000	84.3	NA
Philippines	737,000	84.8	+4.1
Pakistan	608,000	83.8	+5.1
Nigeria	479,000	89.1	+6.0
DRC	314,000	83.2	+7.2
South Africa	280,000	75.5	+0.7
Vietnam	172,000	98.5	+0.6
Ethiopia	156,000	95.5	NA
Kenya	128,000	89.3	+3.9
Thailand	111,000	87.2	NA
Brazil	105,000	88.5	-3.4
Uganda	94,000	88.9	+3.4
Russia	56,000	70.5	+5.9
Cameroon	44,000	63.0	-11.4
Ukraine	36,000	66.2	NA
Sierra Leone	25,000	90.6	NA
Liberia	16,000	87.9	NA

→ Encouraging, with caveats




Insights into TB vaccine acceptability among adolescents in Khayelitsha through community engagement



Adolescents (400), Khayelitsha, South Africa

High acceptability, but reasons for not sure/no often due to lack of understanding about TB risk

2. Adolescent reluctance/willingness to vacccinate



=> Encouraging, but education necessary



Willingness to receive a future adult tuberculosis vaccine in Lusaka, Zambia: Perspectives from community members and healthcare workers.




Adjusted Probability (%)

Kerkhoff et al, UCSF

Aim - To reach adult community members and HCWs in high TB burden settings, it is crucial to understand both preliminary willingness to receive a TB vaccine and communication preferences to design strategies to optimize demand and acceptance.

Zambia community (400) and HCWs (100) from low covid vx uptake communities



→ Encouraging, but education necessary



Acceptability of a novel TB vaccine or BCG booster among adults, caretakers of adolescents and adolescents in Manhiça District, southern Mozambique



Garcia-Basteiro, Manhica Health Research Center (CISM), Mozambique

Aim - Document intention to receive a new TB vaccine or BCG booster dose among adults, adolescents (aged 9-17) and their caretakers, in Manhiça, southern Mozambique.

Overall, intention to receive a new TB vaccine or a BCG booster among adults and adolescents is high in southern Mozambique Table. Intention to vaccinate by group and gender for new TB vaccine or a BCG booster dose

	Adult			Adolescent		Caretaker			
Characteristic	Male N = 59 ¹	Female N = 92 ¹	Overall N = 151	Male N = 14 [™]	Female N = 27	Overall N = 41	Male , N = 5'	Female N = 44	Overal N = 49
Would Receive New TB Vaccine									
Yes	44 (75%)	68 (74%)	112 (74%)	11 (79%)	25 (93%)	36 (88%)	5 (100%)	31 (70%)	36 (73%)
No	11 (19%)	4 (4.3%)	15 (9.9%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (9.1%)	4 (8.2%)
Maybe	4 (6.8%)	20 (22%)	24 (16%)	3 (21%)	2 (7.4%)	5 (12%)	0 (0%)	9 (20%)	9 (18%)
Would Receive BCG Booster									
Yes	54 (92%)	71 (77%)	125 (83%)	11 (79%)	26 (96%)	37 (90%)	5 (100%)	39 (89%)	44 (90%)
No	2 (3.4%)	8 (8.7%)	10 (6.6%)	0 (0%)	1 (3.7%)	1 (2.4%)	0 (0%)	2 (4.5%)	2 (4.1%)
Maybe	3 (5.1%)	13 (14%)	16 (11%)	3 (21%)	0 (0%)	3 (7.3%)	0 (0%)	3 (6.8%)	3 (6.1%)

=> Encouraging



Willingness to receive a future TB vaccine among pregnant women living in Brazil, Ghana, Kenya, and Pakistan




Limaye et al, JHU

Our study assessed the willingness of pregnant women across four countries - Brazil, Ghana, Kenya, and Pakistan to receive a future TB vaccine.

~400 per country

We surveyed 1597 women total. When asked about their intentions to receive a future TB vaccine, the majority of women in each country indicated that they would "definitely intend to receive a TB vaccine": 77.9% in Brazil, 65.6% in Ghana, 61.5% in Kenya, and 80.2% in Pakistan



=> Encouraging



- Now standardised survey questions available, to improve comparability
- Contact <u>rebecca.clark@lsthm.ac.uk</u>



Highlights



Impressive country preparedness

Preparing the landscape for TB vaccines: South Africa's strategic planning

First data on new (TB) vaccine acceptability

- Generic vaccines in TB HBCs
- TB Vx HCW/community in Zambia; pregnant women in 4 countries; adolescents in Khayelitsha; adolescents in Mozambique
- Standardised survey questions available

Useful modelling/framework activities

- What to do if vaccine doses are limited? & Fair allocation frameworks?
- TB vaccine impact models being developed <u>in</u> LMICs India at conf (Jessy); S Africa, Indonesia, Brazil coming...



'Facing up to reality— What to do if M72/AS01E doses are limited?'




Clark et al, LSHTM

Aim - used modelling to investigate the difference in impact from varying the number of vaccine doses available and varying the country-specific order of vaccine introduction.

Country introduction order:

- Historically Informed
- TB incidence rate/ M72 trial countries first



=> Makes a big difference, especially at low dose availability



Navigating the unknown: Ensuring equitable TB vaccine access to maximize health impact



Driving innovation from discovery to access

Limaye et al, JHU

A scoping literature review is underway to identify key principles and strategies from vaccine introduction strategies

Key considerations include prioritizing based on need, maximizing health impact, ensuring equity, access, and affordability

The goal is to create a transparent, evidencebased framework that informs national and global policy under conditions of limited supply, while market shaping and communication efforts work toward meeting global demand

ILLUSTRATIVE SHARED LIMITED VACCINE SUPPLY PRINCIPLES















Prioritize protecting public health by reducing severe illness and death, especially for high-risk groups and essential workers. **Balance individual and societal needs** for maximum societal impact.

Ensure transparent, inclusive, datadriven decisions based on ethical principles, with input from affected groups and ongoing public engagement to promote legitimacy and acceptance.

Focus on **areas with the highest disease burden** where vaccination programs can have the greatest impact. Maximize lives saved by targeting regions with the highest need.

Communicate vaccine allocation criteria clearly, including their ethical basis, to **build public trust and ensure accountability** in the vaccination process.

Treat all individuals with equal dignity and ensure non-discriminatory vaccine distribution. Use impartial criteria and, if necessary, random or weighted selection to ensure fairness.

Use the **best available scientific evidence** to guide vaccine phases, adapting as knowledge about disease risk and vaccine effectiveness evolves.

Give some priority to countries involved in vaccine development, but prioritize areas with the highest health impact. In cases of equal need, contributing countries may be given preference.



TB vaccine impact models being developed <u>in</u> LMICs – India at conf (Jessy); S Africa, Indonesia, Brazil coming... Jessy Joseph et al, IAVI (India)


Advancing evidence-informed in-country decisionmaking for new TB vaccine introduction: A responsive and integrated vaccine modelling approach from India

Aim - used modelling to investigate the difference in impact from varying the number of vaccine doses available and varying the country-specific order of vaccine introduction.

Ву

- Historically Informed
- TB incidence rate/ M72 trial countries first

=> Make a big difference, especially at low dose availability



Driving innovation from discovery to access

Highlights



Impressive country preparedness

Preparing the landscape for TB vaccines: South Africa's strategic planning

First data on new (TB) vaccine acceptability

- Generic vaccines in TB HBCs
- TB Vx HCW/community in Zambia; pregnant women in 4 countries; adolescents in Khayelitsha; adolescents in Mozambique
- Standardised survey questions available

Useful modelling/framework activities

- What to do if vaccine doses are limited? & Fair allocation frameworks?
- TB vaccine impact models being developed <u>in</u> LMICs India at conf (Jessy); S Africa, Indonesia, Brazil coming...





Enabling Factors, Community Engagement & Advocacy Shaun Palmer





Meet the committee



This was the first Forum with a dedicated Community Engagement Committee.

The committee members led the development of the Community Declaration and spoke in plenaries across the program.



Keyuri Arvind Bhanushali Survivors Against TB, India



Peter Ngo'la Owiti GAVI CSO Steering Committee, Kenya



Paulina Siniatkina TBpeople, Netherlands



Ani Herna Sari Rekat Peduli, Indonesia



Patrick P. Agbassi Global TB CAB| Envopharm, Côte d'Ivoire



Ezio Távora Rede-TB, Brazil



Rosa Herrera Global TB CAB | Universidad Autónoma de Durango, Campus Mexicali, Mexico



Jackie Cuen We Are TB/Somos TB, USA



Shaun Palmer IAVI | TB Vax ARM, Netherlands



Vanessa Mwebaza Muwanga WGNV, South Africa





Driving innovation from discovery to access

Community Declaration

What is it?

- An opportunity to amplify our collective voice
- Share our demands to attendees of the 7th Global Forum and to leaders and decision makers about the urgent need to invest in TB vaccine development and introduction



Community Declaration of the 7th Global Forum on TB Vaccines

TULOBAL FORUM

Distinguished leader.

On behalf of representatives of the global TB community, including the 7th Global Forum Community Engagement Committee and the undersigned, we hereby share the demands of TB i affected communities for the development can dimplementation of new TB vaccines.

It is an injustice that over 3.000 people die from T8 every single sky. Most of these heres are lost in communities and valuenciate to exploitation due to deep inequalities. This a signalised disease that shatters families and runs lives. It is uncceptable that we still rely on the centrary eld Barlibs communities and (GCI) vaccine, which is largely informative in addrescares and addits, among whom 90% of T0 disease occurs. The fanct that we still de not have effective T0 vaccines is a clear sign that affected communities are not a real priority. It is time to hange the story.

Ending TBI is about ensuring everyone gets a diri shot at a healthy life. To achieve this by 2020, we need multiple new vaccines that work for averyone, are available, accessible, and acceptable to all no matter whole they live, and are allordable, especially to high burden countries. We must urgently fast-track TB vaccine research, particularly crucial late-stage trials, while at the same time perpending for their quick and equitable distribution.

New TB vaccines will save millions of lives and protect the wellbeing and prosperity of billions. TB vaccines can also help control dirug-resistant TB and build stronger health and research systems, investing in TB vaccines now will boost economic growth and improve public health, while leaving the world better prepared to respond to future arithome pandemics.

It is a share that funding for TB vaccine research has never passed 51.57 mBion a year. Our leaders need to act fast to keep their promises made at the 2023 United Nations (UNI) High-Level Moeing on TB to develop and deliver at least one new TB vaccine by 2028. To reach this goal, UN Member States Committed to invest 55 billion annually in TB research by 2029, with \$1.25 billion for vaccines. Annual funding must herefore in crasse by almost 10-fail.

- We need to overcome chronic underfunding and speed up development and access.
- We demand joint, increased, and sustained funding of TB vaccine research and rollout, with coordinated paths for their accelerated approval and implementation. All countries should contribute their fair share, including high burden countries.
- We demand that vaccines developed with public funds are universally and equitably
 accessible, and affordable to all countries. This means attaching access requirements to
 public funding, supporting the necessary technology transfer, and remarking unfair
 intelectual property barries.
- We demand an independent monitoring and evaluation mechanism to ensure
- accountability of all commitments and investments in TB research. • We demand strengthened research, manufacturing, and delivery capacity in high
- burden regions to ensure their leadership in TB vaccine research and implementation

7th Global Forum on TB Vaccines | October 2024 | www.sbvaccinesforum.org | Contact spalmer.Elavi.org





- We demand that the WHO TB Vaccine Accelerator Council fully uses its influence by leading a campaign to raise the resources needed for TB vaccine research and rollout.
- We must listen to communities, address their concerns and needs, build public trust and awnership, and guarantee a fair process to access new 78 vaccines.
- We demand that communities are meaningfully involved at every step of T8 vaccine development and rollout, not just as trial participants, but as decision makers. Their involvement must follow the highest relival standards to ensure drainess and transparency and shape activities like trial design, post-trial access, and pricing.
- We demand that reasersh includes all populations, age groups, and regions. This
 includes pregnant and lactating women and people, children, people ingo with Hya
 prisones, people in extreme poverty, hamiles people, people with dsabilities, healthcare
 workers, and these who previously had 10.4 high burden regions must be represented in
 clinical trials, including Lath America which is missing from onging studies.
- We demand a review of ethical standards and the prioritization of socio-behavioral
 research to guarantee participation of those most at risk in trials and rollout. We must
 uphold the Human Right to enjoy and share the benefits of scientific progress and its
 applications. No one should be left behind.
- We demand that new TB vaccines are part of a comprehensive package of care that addresses all aspects of TB. This must include support for mental health, finances, and nutrition, address related health issues such as HV and diabetes, reach remote and marginalized communities, and be available through both public and private providers.
- We demand clear, simple communication in local languages, shared through community networks. This is key to help people understand chrical trials and the benefits of new TB vaccines. This will tackle vaccine hesitancy, mistrust, and misinformation, while also building demand for vaccines in our communities.

The world must not prioritize pharmacentical profits over the leves and wellbeing of people allitons of people well benefit from investments in new TB vaccines. We stand in oblidatily with all people affected by TB in domaining cut leaders and dickion makers immediately mobilize the political well and investments needed to make new TB vaccines a reality this decide. There is no time to lose – millies of thes depend on your action.



7th Global Forum on TB Vaccines | October 2024 | www.tbvaccinesforum.org | Contact spolmer:Blavilorg





Community Declaration

The process

- Initial feedback from the global TB community from multilingual webinar in August
- First draft prepared by the Committee, based on the webinar feedback
- Online consultation survey to collect feedback on the first draft
- Final version prepared based on the survey feedback
- Open for public sign on 17 Sep 10 Oct
- Presented during the Declaration in the Opening Ceremony

Available in English, French, Hindi, Indonesia, Portuguese, Russian, and Spanish



07 NOBAL FORUM

Community Declaration of the 7th Global Forum on TB Vaccines

Distinguished leader,

On behalf of representatives of the global TB community, including the 7th Global Forum Community Engagement Committee and the undersigned, we hereby share the demands of TB affected communities for the development and implementation of new TB vaccines.

It is an injustice that over 3.500 people die from TB overy single day. Most of these lives are lost in communities and valuterable to exploitation due to deep inequilities. This a signatured disease that shatters families and ruins lives. It is uncesptable that we still rely on the century-old Bacilito Camterto-Cusints (IGC) vaccine, which is largely informative in addrescence and adults, among whom 50% of TB disease occurs. The fact that we still do not have effective TB vaccines is a clear sign that affected communities are not a real priority. It is time to change the story.

Ending TB is about ensuring everyone gets a fair shot at a headity iffe. To achieve this by 2000, we need multiple networkness that work for overyone, are available, accessible, and acceptable to all no matter where they live, and are affordable, especially to high burden countries. We must urgently fast track TB vaccine research, particularly crucial late-stage trials, while at the same time preparing for their quick and equitable distribution.

New TB vaccines will save millions of lives and protect the wellbeing and prosperity of billions. TB vaccines can also help control drug-resistant TB and build storogen health and research systems, investing in TB vaccines now will boost economic growth and improve public health, while leaving the world better prepared to respond to future arbitrom pandemics.

It is a share that funding for T0 vaccine research has never passed 5145 million a year. Our leaders need to act fact to keep their promises made at the 2023 United Nations (UNI High-Level Making on T15 to develop and deliver at least one new T0 vaccine by 2028. To reach this paul, UN Member States committed to invest 55 billion annually in T8 mearch by 2027, with 51.25 billion for vaccines. Annual funding must herefore increase by admost 16-fold.

te need to overcome chronic underfunding and speed up development and access.

- We demand joint, increased, and sustained funding of TS vaccine research and rollout with coordinated paths for their accelerated approval and implementation. All countries shudid contribute their fair share, including high burden countries.
- We demand that vaccines developed with public funds are universally and equitably
 accessible, and affordable to all countries. This means attaching access requirements to
 public funding, supporting the necessary technology transfer, and removing unfair
 intelectual property barries.
- We demand an independent monitoring and evaluation mechanism to ensure accountability of all commitments and investments in TB research.
- We demand strengthened research, manufacturing, and delivery capacity in high burden regions to ensure their leadership in TB vaccine research and implementation

7th Global Forum on TB Vaccines | October 2024 | www.sbvaccinesforum.org | Contact spalmer.Riavi.org



TiLOBAL FORUM

 We demand that the WHO TB Vaccine Accelerator Council fully uses its influence by leading a campaign to raise the resources needed for TB vaccine research and rollout

We must listen to communities, address their concerns and needs, build public trust and ownership, and guarantee a fair process to access new TB vaccines.


- We demand that communities are meaningfully involved at every step of T8 vaccine development and rollout, not just as trial participants, but as decision makers. Their involvement runst follow the highest terkial standards to ensure drainess and transparency and shape activities like trial design, post-trial access, and pricing.
- We demand that research includes all populations, age groups, and regions. This
 includes pregnant and lactating women and people, children, people living with HV,
 prisones, people in eatreme powerty, homeless people, people with duabilities, healthcare
 workers, and these who pervisors had TD. All high burden regions must be represented in
 clinical trials, including Laint America which is missing from ongoing studies.
- We demand a review of ethical standards and the prioritization of socio-behavioral
 research to guarantee participation of those most at risk in trials and rollout. Vie must
 uphold the Human Right to enjoy and share the benefits of scientific progress and its
 applications. No one should be left behind.
- We demand that new TB vaccines are part of a comprehensive package of care that addresses all aspects of TB. This must include support for mental health, finances, and nutrition, address related health issues such as HIV and diabetes, reach remote and marginalized communities, and be available through both public and private providers.
- We demand clear, simple communication in local languages, shared through community networks. This is key to help people understand clinical trials and the benefits of new T8 vectors. This will tackle vaccine hesitancy, misruts, and misinformation, while also building demand for vaccines in our communities.

The world must not prioritize pharmaceutical profits over the lives and weltbeing of people Billison of people will benefit from investments in new TB vaccines. We stand in solidarity with all people affected by TB is demanding out leaders and decision makers immediately mobilize the political will and investments needed to make new TB vaccines a reality this decade. There is no time to lose – millines of these depend on your zoton.

Yours sincerely, The undersigned

7th Global Forum on TB Vaccines | October 2024 | www.tbyaccinesforum.org | Context spalmer@lawl.org





8-10 October 2024 Rio de Janeiro, Brazil

Driving innovation from discovery to access

Thank you to the **1,410** individuals and organizations from **81** countries who signed the Community Declaration!

Read the declaration, share our demands.





bit.ly/7GFTBV comdecSign

@GlobForumTBVax #7GFTBV | #GlobalForumTBVax









Active participation, meaningful visibility





Paulina Siniatkina presenting the community declaration during the Opening Ceremony (Tue, 8 Oct 2024)



TB IS OVER (if you want it) – art installation by Paulina Siniatkina outside of the Grande Sala, Cidade das Artes



Active participation, meaningful visibility



Committee members spoke at each of the plenary sessions



Ezio Távora, Plenary 1: From discovery to access and Plenary 5: Innovative approaches to TV vaccine R&D



Peter Ngo'la Owiti, Plenary 2: Global & regional enablers for the introduction of new TB vaccines



Keyuri Bhanushali, Plenary 3: Advancing TB vaccine clinical development



Patrick Agbassi, Plenary 4: Country scale-up & implementation of new TB vaccines



Jackie Cuen & Shaun Palmer, Plenary 6: Enabling TB vaccine development through funding political will, open science, & engaged communities

